Brand vs generic Concerta: are the generics the same?

Generic Concerta is one of the few cases where the FDA publicly downgraded generics of a widely used drug, so adults on methylphenidate extended-release tablets often ask whether the generic they get is truly the same. The short answer, as of October 2026: the marketed generic versions are rated by the FDA as therapeutically equivalent (AB) to Concerta except one product rated BX (not considered substitutable), and the pharmacy label tells you which manufacturer you received. This page explains the history and how to check.

What "generic" means here

The FDA says a generic medicine has the same active ingredient, strength and dosage form as the brand and is bioequivalent to it. The Orange Book, the FDA's list of approved drugs, then assigns therapeutic equivalence codes. An "AB" code means FDA considers the product therapeutically equivalent, with any bioequivalence questions resolved by evidence. A "BX" code means "the data are insufficient to determine therapeutic equivalence," and such products "are presumed to be therapeutically inequivalent" until FDA decides otherwise.

The Orange Book preface also notes that therapeutically equivalent products can differ in shape, release mechanism, inactive ingredients and packaging. When such differences matter for a particular patient, it says, the prescriber may require that a specific product be dispensed.

The 2014 to 2016 history

In November 2014, the FDA announced concerns that two generic versions of Concerta, made by Mallinckrodt and Kudco, "may not produce the same therapeutic benefits for some patients." Its analysis found that in some people those products might deliver the drug more slowly during the 7- to 12-hour range. The FDA changed their codes from AB to BX, meaning they could still be prescribed but were "no longer recommended as automatically substitutable." In October and November 2016 the FDA proposed withdrawing approval of both. The same FDA page noted that Janssen's authorized generic, marketed by Actavis and "identical to Janssen's Concerta," was found bioequivalent and substitutable, and that the FDA approved another generic in October 2016.

Where things stand in October 2026

These counts come from the Orange Book data files dated October 9, 2026, filtered to marketed (prescription) methylphenidate extended-release tablets in Concerta's strengths. No Mallinckrodt-named product appears there as marketed. Relexxii, a separately approved methylphenidate extended-release tablet, has its own application and no therapeutic equivalence code, so it is not an automatic substitute for Concerta. Authorized generics (the brand maker's own product sold under a generic label) are not listed separately in the Orange Book, and whether one is currently on shelves was not confirmed for this guide.

How to tell what you received

• Read the label. In New York, Education Law section 6816-a requires the pharmacist to put the drug product's name, strength and manufacturer on the container label unless the prescriber states otherwise, and to record the manufacturer on the prescription.
• Ask the pharmacist which company made it and whether it is AB-rated to Concerta.
• Keep a note of the manufacturer each month, especially if you notice a change in how long the medicine seems to last.

The FDA's own advice from the 2014 episode still applies: if a methylphenidate ER product does not seem to work as before, contact the pharmacy to find out the manufacturer and talk to the prescriber. The FDA also wrote that patients "should not make changes to their treatment except in consultation with their health care professional."

Substitution rules in New York

New York Education Law section 6816-a says a pharmacist "shall substitute a less expensive drug product containing the same active ingredients, dosage form and strength," as long as the prescriber has not prohibited substitution and the product is on the state's list of substitutable drugs. In other words, in New York generic substitution is the default, and the prescriber, not the patient at the counter, controls whether a brand must be dispensed. New Jersey has its own generic substitution law, which was not reviewed for this page; ask the pharmacist how it applies to your prescription.

Cost, coverage and supply

Brand and generic prices, and how a plan covers each, can differ a lot. What ADHD medication costs in New York explains formularies and discount programs. Supply is a separate issue: as of October 19, 2026, the FDA shortage database lists methylphenidate extended-release tablets as a current shortage, so the manufacturer you receive may change month to month. What to do when your pharmacy is out of stock and transferring an ADHD prescription between pharmacies cover your options. Schedule II rules still apply to every version: no refills in New York (10 NYCRR 80.67) or New Jersey (N.J.A.C. 13:45H-7.9). See New York's rules and New Jersey's rules.

For the brand label itself, see Concerta for adults. The wider topic is covered in generic ADHD medications and authorized generics.

Questions worth asking

• Which manufacturer is my pharmacy dispensing, and is it AB-rated to Concerta?
• If I notice a difference after a manufacturer change, how should I report it?
• Would my prescriber require a specific product, and would my plan cover it?
• What is the backup plan if my usual product is out of stock?

Talking it through with a prescriber

Dr. Shershow is a psychiatrist focused on adult ADHD, licensed in New York and New Jersey, who provides medication management when medication is appropriate. The office can tell you how prescriptions are handled; the pharmacy can tell you which product it stocks. This page is general information, not advice to change any medication.